Rapid Micro Biosystems Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Revenue and Provides 2022 Revenue Outlook

Written by Customer Service on January 9, 2022. Posted in Public Companies.

Full year 2021 commercial revenue expected to be between $21.3 million and $21.7 million Full year 2022 commercial revenue outlook between $27 million and $32 million Company to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022 LOWELL, Mass., Jan. 09, 2022 (GLOBE NEWSWIRE) — Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced preliminary unaudited fourth quarter and full year 2021 revenue. The Company also announced its full year 2022 commercial revenue outlook. Preliminary Unaudited Fourth Quarter 2021 Revenue The Company currently expects total revenue of between $4.7 and $5.2 million in the...

RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Financial and Operational Results

Written by Customer Service on January 9, 2022. Posted in Public Companies.

ALISO VIEJO, Calif., Jan. 09, 2022 (GLOBE NEWSWIRE) — (NASDAQ: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced preliminary unaudited financial and operational results for the fourth quarter and fiscal year 2021. Preliminary Unaudited Results Preliminary unaudited fourth quarter 2021 revenue is expected to be approximately $8.4 million, representing growth of approximately 71% compared to the prior year period, driven by: Sale of 45 Light Delivery Devices (LDD™s), expanding the installed base to 206 LDDs as of December 31, 2021; and Sale of 2,959 Light Adjustable Lenses (LAL®s). Preliminary unaudited 2021 fiscal year revenue is expected to be approximately $22.6 million, representing growth of approximately 54% compared to the...

Emergent BioSolutions Announces 2022 Financial Guidance, Provides Preliminary 2021 Results

Written by Customer Service on January 9, 2022. Posted in Public Companies.

Expects a re-baseline of operations with stable revenue contributions from core products and services business in 2022, guiding to total revenues of $1.45 billion at the midpoint and Adjusted EBITDA margin of 21.5% at the midpoint Reports preliminary 2021 total revenues of $1.78 billion at the midpoint and Adjusted EBITDA of $513 million, or 29%, at the midpoint, both in line with prior guidance given in November 2021 GAITHERSBURG, Md., Jan. 09, 2022 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced its financial guidance for 2022 and selected preliminary unaudited financial results for 2021. “This past year we celebrated wins across the business and overcame our share of challenges, which have made our organization stronger,” said Robert G. Kramer, president and CEO of Emergent BioSolutions. “We remain...

Exagen Inc. and Queen Mary University of London Announce Exclusive License and Collaboration to Develop Novel Patented Molecular Signatures for Rheumatoid Arthritis Biologic Therapeutic Selection

Written by Customer Service on January 9, 2022. Posted in Public Companies.

SAN DIEGO, Jan. 09, 2022 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, and Queen Mary University of London, announced today the execution of a research collaboration and exclusive license agreement. The collaboration will focus on development and optimization of patent-pending precision medicine approaches, based on RNA expression signatures, to personalize therapeutic agent selection for rheumatoid arthritis (RA) patients. Both parties will contribute to the development of the patent-pending assays, leading to the commercialization of novel molecular assays that segment patients according to gene expression in their synovial tissue biopsies. RA is estimated to affect approximately two million patients in the United States and be twice as prevalent in women as in men and can be...

Beam Therapeutics Reports Progress Across Ex Vivo and In Vivo Pipeline of Base Editing Therapeutics and Outlines Key Anticipated 2022 Milestones

Written by Customer Service on January 9, 2022. Posted in Public Companies.

First Subject Anticipated to be Enrolled in BEAM-101 Phase 1/2 Clinical Trial for the Treatment of Sickle Cell Disease in the Second Half of 2022 BEAM-301 Named as Fourth Development Candidate for the Treatment of Glycogen Storage Disease Type Ia Nomination of Two Additional Development Candidates Anticipated in 2022 Company to Present Pipeline and Business Updates at 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 2:15 p.m. ET CAMBRIDGE, Mass., Jan. 09, 2022 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today outlined anticipated 2022 milestones across its ex vivo programs targeting editing of hematopoietic stem cells (HSCs) and T cells and in vivo programs targeting editing of liver cells leveraging lipid nanoparticles...

M	T	W	T	F	S	S
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30
31

Day: January 9, 2022